mapping the effectiveness and risks of glp-1 receptor agonists pdf SGLT2 Inhibitors in Diabetic Kidney Disease: Evolving Evidence and Clinical Application Mapping the effectiveness and risks
Description
GLP-1 was identified as a key incretin hormone in the 1980 s (Lund et al
2012;2:e51e51
doi: 10.3390/ijms21093165 [DOI] [PMC free article] [PubMed] [Google Scholar] 14
Microdosing uses a fraction25% or lessof the standard GLP-1 maintenance dose
00014-3/asset/c6c68f71-1303-4dbd-81fc-c7e57d64925d/main.assets/gr2_lrg.jpg)
The obesity epidemic affecting our youth requires innovative approaches, and GLP-1 RAs may represent an important advancement in our therapeutic armamentarium
Exenatide inhibits NF-B and attenuates ER stress in diabetic cardiomyocyte models
